VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
XNCRXencor, Inc.
$12.64$927M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksXNCRPrice Target
XNCR logo

Xencor, Inc. (XNCR) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 27 analysts

179.3% Below Target

XNCR trades 179.3% below Wall Street's consensus target of $35.30.

Current Price$12.64
Average Target$35.30
Target
Current
Low$18.00
Median$31.00
High$58.00

Analyst Target Range

Forward P/E—
PEG Ratio—
Implied Growth-69.5%
(Declining)
Analyst Spread113.3%
(Wide Disagreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$12.64
Consensus$35.30
High$58.00
Low$18.00

Consensus Scenario Assumptions

The base valuation assumes XNCR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 27 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 27 published analyst recommendations for XNCR

24/27 analysts are bullish
+44
BearishBullish
Weighted analyst sentiment score based on 27 ratings
ConsensusBuy
Coverage27 Analysts
Net Score+44
Bull / Bear89% / 4%
Strong Buy14%
Buy2385%
Hold27%
Sell14%
Strong Sell00%
Strong Buy
14%
Buy
2385%
Hold
27%
Sell
14%
Strong Sell
00%
Recommendation Mix89% Buy · 7% Hold · 4% Sell
Buy (24)Hold (2)Sell (1)

XNCR Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Xencor, Inc. (XNCR) has a Wall Street consensus price target of $35.30, based on estimates from 27 covering analysts. With the stock currently trading at $12.64, this represents a potential upside of +179.3%. The company has a market capitalization of $927M.

Analyst price targets range from a low of $18.00 to a high of $58.00, representing a 113% spread in expectations. The median target of $31.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.

The current analyst consensus rating is Buy, with 24 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, XNCR trades at a trailing P/E of -10.2x. Analysts expect EPS to grow -69.5% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+32.1%
Industry Consensus
Avg Forward P/E
20.6x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
RCUS logo
RCUSArcus Biosciences, Inc.
$2.4B$24.31$31.00
+27.5%
Buy—18
MGNX logo
MGNXMacroGenics, Inc.
$263M$4.13$6.00
+45.3%
Buy—22
IMVT logo
IMVTImmunovant, Inc.
$7.3B$35.34$45.00
+27.3%
Buy—23
ALKS logo
ALKSAlkermes plc
$7.5B$44.99$49.50
+10.0%
Buy—28
ZYME logo
ZYMEZymeworks Inc.
$1.7B$23.14$40.67
+75.8%
Buy16.9x20
PTGX logo
PTGXProtagonist Therapeutics, Inc.
$7.3B$112.86$117.25
+3.9%
Buy28.0x26
ABBV logo
ABBVAbbVie Inc.
$383.2B$216.63$256.92
+18.6%
Buy15.2x41
REGN logo
REGNRegeneron Pharmaceuticals, Inc.
$63.4B$609.94$836.00
+37.1%
Buy13.1x48
ALNY logo
ALNYAlnylam Pharmaceuticals, Inc.
$37.1B$278.09$454.27
+63.4%
Buy37.1x52
INCY logo
INCYIncyte Corporation
$19.6B$98.22$109.80
+11.8%
Buy13.0x44

XNCR — Frequently Asked Questions

Quick answers to the most common questions about buying XNCR stock.

What is the XNCR stock price target for 2026?

The consensus Wall Street price target for XNCR is $35.3, representing 179.3% upside from the current price of $12.64. With 27 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is XNCR a buy, sell, or hold?

XNCR has a consensus rating of "Buy" based on 27 Wall Street analysts. The rating breakdown is predominantly bullish, with 24 Buy/Strong Buy ratings. The consensus 12-month price target of $35.3 implies 179.3% upside from current levels.

Is XNCR stock overvalued or undervalued?

XNCR's current price is $12.64 with a consensus target of $35.3 (179.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.

How high can XNCR stock go?

The most bullish Wall Street analyst has a price target of $58 for XNCR, while the most conservative target is $18. The consensus of $35.3 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover XNCR stock?

XNCR is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 23 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the XNCR stock forecast?

The 12-month XNCR stock forecast based on 27 Wall Street analysts shows a consensus price target of $35.3, with estimates ranging from $18 (bear case) to $58 (bull case). The median consensus rating is "Buy".

Should I buy XNCR stock?

Wall Street analysts are very optimistic on XNCR, with a "Buy" consensus rating and $35.3 price target (179.3% upside). 24 of 27 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do XNCR price targets vary so much?

XNCR analyst price targets range from $18 to $58, a 113% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $35.3 consensus represents the middle ground.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare